What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to furnish Amgen's press release announcing its unaudited financial results for the three months and year ended December 31, 2017. It also details the non-GAAP financial measures the company uses and explains the rationale behind excluding certain items from GAAP reporting.

What are the key differences between Amgen's GAAP and non-GAAP financial measures?

Amgen's non-GAAP measures exclude items such as amortization of purchased intangible assets, restructuring initiative costs, expenses from legal judgments/settlements, and the impact of U.S. corporate tax reform. The company believes these exclusions provide a more meaningful evaluation of current operating performance and comparability across periods.

What is Free Cash Flow (FCF) and why does Amgen report it?

Free Cash Flow (FCF) is calculated by subtracting capital expenditures from operating cash flow, both determined in accordance with GAAP. Amgen reports FCF as an additional measure of the company's liquidity, providing insight into the cash generated from operations after accounting for necessary investments in its business.

Does the information in this filing automatically update Amgen's other SEC filings?

No, the information furnished under Item 2.02 in this Current Report, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It will not be incorporated by reference into any of Amgen's other SEC filings unless specifically stated.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. filed an 8-K report on February 1, 2018, primarily to furnish a press release detailing its unaudited financial results for the fourth quarter and full year ended December 31, 2017. The report highlights Amgen's use of non-GAAP financial measures, such as non-GAAP earnings per share and free cash flow, to provide investors with a clearer understanding of the company's operational performance and liquidity. These non-GAAP metrics exclude certain items like acquisition-related expenses, restructuring costs, legal settlements, and the impact of U.S. corporate tax reform, which management believes are not indicative of ongoing business operations. The company emphasized that these non-GAAP presentations are intended to supplement GAAP results by facilitating comparisons across periods and treating acquired intellectual property similarly to internally developed assets. Investors should note that this information is furnished and not deemed "filed" for regulatory purposes, meaning it does not automatically become part of subsequent SEC filings unless specifically incorporated.

Key Highlights

1Amgen released its unaudited Q4 and full-year 2017 financial results via a furnished press release on February 1, 2018.
2The company provided both GAAP and non-GAAP financial measures, including non-GAAP EPS, operating income, and net income.
3Key non-GAAP adjustments include acquisition-related expenses, restructuring costs, legal settlements, and the impact of U.S. tax reform.
4Free Cash Flow (FCF) was also presented as a measure of liquidity, calculated as operating cash flow less capital expenditures.
5Amgen uses non-GAAP measures to enhance comparability and provide insights into ongoing business operations.
6The furnished information in this 8-K is not considered "filed" under Section 18 of the Exchange Act and does not automatically incorporate into future SEC filings.
7David W. Meline, EVP and CFO, signed the report, indicating executive financial oversight.

AMGEN INC 8-K Report, Financial Results (Feb 1, 2018)

Summary

Key Highlights

Frequently Asked Questions